Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of ASC 60 in patients with advanced solid tumors

Next Previous
Trial Profile

A phase 1 study of ASC 60 in patients with advanced solid tumors

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASC 60 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 06 Apr 2022 According to an Ascletis media release, Investigational New Drug (IND) application of ASC60 for treatment of advanced solid tumors has been approved by China National Medical Products Administration.
  • 30 Mar 2022 New trial record
  • 27 Mar 2022 According to an Ascletis media release, the application of the Phase I study of ASC60 in patients with advanced solid tumors has been submitted to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top